Highly active csf1r inhibitor compound

A compound of formula I or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, a mixture of stereoisomers or a racemic mixture of stereoisomers:

• wherein, X represents CRaRa′,
• NRa, —C(O)—, O, S, S(O), S(O)2;
• R1 and R2, together with the carbon atom directly attached thereto form a saturated or unsaturated 3 to 12 membered cycloalkyl or cycloheteroalkyl ring, the heterocycloalkyl group contains at least one heteroatom selected from O, N and S, the cycloalkyl group or heterocycloalkyl group can be optionally substituted by 0, 1, 2, 3 or 4 substituents each independently selected from the following halogen, hydroxy, C1-C8 alkyl, C3-C8 cycloalkyl, C3-C8 heterocycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, C1-C8 haloalkyl, C1-C8 alkoxy, C1-C8 haloalkoxy, C3-C8 cycloalkoxy, C3-C8 heterocyclic alkoxy, —S—(C1-C8) alkyl, —S—(C3-C8) cycloalkyl, —S—(C3-C8) heterocycloalkyl, cyano, nitro, —(C0-C8)alkyl-NR9Ra′, —C═NRa, —O—Cy1, —O—(C0-C8)alkyl-Cy1, —(C2-C8)alkenyl-Cy1, —(C2-C8)alkynyl-Cy1, —C(O)ORa, —C(O)Ra, —OC(O)Ra, —C(O)—NRaRa′, —NRa—C(O)—Ra, —NRa—C(O)—ORa, —(C1-C8)alkyl-NRa—C(O)Ra, —SO2—NRaRa′ and —SO2Ra;
• R3 and R5 each independently represent hydrogen, halogen, C1-C8 alkyl, C1-C8 alkoxy, C3-C8 cycloalkyl, C3-C8 heterocycloalkyl, halogenated C1-C8 alkyl, hydroxyl, amino, nitro, cyano, —C(O)ORa, —OC(O)Ra, —C(O)—NRaRa′, —NRa—C(O)—Ra, —NRa—C(O)—ORa, —(C1-C8)alkyl-NRa—C(O)Ra, —SO2—NRaRa′ or —SO2Ra;
• R4 represents Cy2, —NHC(O)Ra, —NHC(O)NRaRa′, —C(O)Ra, —c(O)NRaRa′, —S(O)2Ra, —S(O)2NRaRa′, NHS (O)2Ra or —NHS(O)2NRaRa′;
• wherein, Cy1 and Cy2 each independently represent a 5-12 membered ring which was independently substituted by 0, 1, 2, 3 or 4 substituents, preferably a 5-12 membered aryl group or a 5-12 membered heteroaryl group;
• more preferably a 5-6 membered aryl group or a 5-6 membered heteroaryl group, wherein the substituents are halogen, C1-C8 alkyl, C1-C8 alkoxy, C3-C9 cycloalkyl, C3-C9 heterocycle alkyl, halogenated C1-C8 alkyl, hydroxy, nitro, cyano, —C(O)ORa, —OC(O)Ra, —C(O)—NRaRa′, —NRa—C(O)—Ra, —NRa—(O)—ORa, —(C1-C8)alkyl-NRa—C(O)Ra, —SO2—NRaRa′ and —SO2Ra;
• wherein, Ra and Ra′ independently represent hydrogen, C1-C8 alkyl, C3-C9 cycloalkyl, hydroxyl, halogen, amino, C1-C8 haloalkyl, C1-C8 alkylamino, alkylamino group or Ra, Ra′ together with the atom directly attached thereto form a 3-9 membered cycloalkyl or heterocycloalkyl ring, preferably hydrogen, C1-C8 alkyl or C3-C8 cycloalkyl;
• n is 1, 2 or 3, preferably 1;
• m and o independently represent 0, 1, 2 or 3,
• for the above-defined alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups, can further be substituted with the substituents selected from the following:
• C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, 5-12 membered aryl, 5-12 membered heteroaryl, C1-C8 haloalkyl, C1-C8 alkoxy, C1-C8 alkylthio, halogen, hydroxyl, cyano, sulfonic and nitro;
• for the above-defined substituents, each of the different substituents Ra or Ra′ has its own independent definition.